This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rao, G. Articles by Rothenberg, M. L. Search for Related Content PubMed PubMed Citation Articles by Rao, G. Articles by Rothenberg, M. L. Social Bookmarking                            What's this?

Intraperitoneal Chemotherapy for Ovarian Cancer: Overview and Perspective

Gautam Rao, Marta Crispens, Mace L. Rothenberg

From the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology; Division of Hematology/Oncology, Department of Medicine; and the Vanderbilt University Medical Center, Nashville, TN

Address reprint requests to Mace L. Rothenberg, MD, Division of Hematology/Oncology, Vanderbilt University Medical Center, 777 Preston Research Bldg, Nashville, TN 37232-6307; e-mail: mace.rothenberg{at}vanderbilt.edu

Intraperitoneal (IP) chemotherapy has theoretical, pharmacologic, and clinical advantages over intravenous (IV) chemotherapy in women with optimally debulked epithelial ovarian cancer confined to the abdominal cavity. Consistent, statistically significant improvements in both progression-free and overall survival have been demonstrated in three large phase III trials conducted in the United States during the past 10 years. Nevertheless, concerns over IP drug distribution and systemic absorption, technical challenges of IP catheter placement and the incidence of IP catheter-related complications, and the clinical relevance of these studies have limited the adoption of IP therapy in ovarian cancer. Current interest in the evaluation of molecularly targeted therapies should build on the progress that has been made through the use of IP chemotherapy in women with optimally debulked ovarian cancer.

Supported in part by National Institutes of Health Grant No. 2 K24 CA82301 (M.L.R.).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. G. ZEIMET, D. REIMER, A. C. RADL, A. REINTHALLER, C. SCHAUER, E. PETRU, N. CONCIN, S. BRAUN, and C. MARTH Pros and Cons of Intraperitoneal Chemotherapy in the Treatment of Epithelial Ovarian Cancer Anticancer Res, July 1, 2009; 29(7): 2803 - 2808. [Abstract] [Full Text] [PDF]

				A. Banzato, S. Bobisse, M. Rondina, D. Renier, F. Bettella, G. Esposito, L. Quintieri, L. Melendez-Alafort, U. Mazzi, P. Zanovello, et al. A Paclitaxel-Hyaluronan Bioconjugate Targeting Ovarian Cancer Affords a Potent In vivo Therapeutic Activity Clin. Cancer Res., June 1, 2008; 14(11): 3598 - 3606. [Abstract] [Full Text] [PDF]